Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
复制标题
DOI：
10.1038/s41423-021-00643-6
复制
发表时间：
2021
影响因子：
24.1
通讯作者：
Mingzhao Zhu
中科院分区：
文献类型：
--
作者：
Wenjun Wang;Baoying Huang;Yanping Zhu;Wenjie Tan;Mingzhao Zhu
To date, the global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has resulted in more than 90 million people infected and over 2 million deaths. A safe and effective vaccine is in high demand. For an effective vaccine, antibody persistence and longterm memory are favorable features. The poor antibody persistence after natural SARS-CoV-2 infection raised concerns about whether a vaccine could induce a long-lasting antibody response and whether a memory recall response would be induced upon reinfection.1,2 Currently, over 200 vaccine candidates have been documented, some of which have advanced to clinical trials with encouraging results. However, to the best of our knowledge, the extent of antibody persistence and long-term memory post vaccination is still unclear. Here, we report that a ferritin nanoparticle (NP)-based SARS-CoV-2 receptor-binding domain (RBD) vaccine induced an efficient antibody response in mice that lasted for at least 7 months post immunization. A high number of memory B cells (MBCs) were maintained and recalled significantly upon antigen challenge.
